戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  potency to non-disease-inducing Ags using a bacterial vaccine.
2 kable improvement in the development of live bacterial vaccines.
3 , and it is now being used for several other bacterial vaccines.
4 emic or mucosal immunizations with viral and bacterial vaccines.
5 ing the use of MIP antigens for inclusion in bacterial vaccines.
6 ustained following vaccination with a killed bacterial vaccine adjuvanted with aluminum hydroxide and
7 hetic CpG-ODNs but not with the DNA of mixed bacterial vaccine and were shown to be phosphorothioate
8 es for the development of safe and effective bacterial vaccines and adjuvants.
9 crobial origin and to an orally administered bacterial vaccine, and plasma-derived IgG Abs to systemi
10                              Generally, oral bacterial vaccines are acid labile and need to be admini
11 e present uncertainty of which live viral or bacterial vaccines can be given to immunodeficient patie
12 metry and computational strategy to identify bacterial vaccine candidates and validate their immunoge
13 ation may be potentially applied to numerous bacterial vaccine candidates, and irradiated bacteria co
14 alysis of 6 civilian studies of mixed killed bacterial vaccines containing pneumococci identified sig
15 stematic review and reanalysis of studies of bacterial vaccine efficacy (VE) in preventing pneumonia
16 n turn, has led to a call for stockpiling of bacterial vaccines for pandemic preparedness.
17 size and nanometer size), we have designed a bacterial vaccine form that exhibits improved efficacy o
18  to multiple pneumococcal serotypes and that bacterial vaccines may play a role in preventing influen
19 e humoral immunity induced by many viral and bacterial vaccines mediates protection that is maintaine
20                                  Recombinant bacterial vaccines must be fully attenuated for animal o
21 ing mutations into candidate live attenuated bacterial vaccines offers a promising approach for the d
22 rld Health Organization coordinated Invasive Bacterial Vaccine Preventable Diseases network, Togo con
23 rt of the World Health Organization Invasive Bacterial-Vaccine Preventable Diseases (IB-VPD) surveill
24 e World Health Organization's (WHO) Invasive Bacterial Vaccine-preventable Diseases Surveillance Netw
25 ion of immature/T1 B cells by TLR ligands or bacterial vaccine rapidly induces T1 cells to divide, pr
26       Nasal and injection vaccination with a bacterial vaccine revealed unique dynamics of IgM and Ig
27 a, as well as stockpiling of antibiotics and bacterial vaccines, should also be high priorities for p
28 has led to many advances in the discovery of bacterial vaccine targets.
29 rradiated Listeria monocytogenes as a killed bacterial vaccine, testing the hypothesis that irradiati
30 e elicited by oral delivery of a recombinant bacterial vaccine, tetanus toxin fragment C (TTFC) was e
31 ecular patterns found in attenuated viral or bacterial vaccines that function as Toll-like receptor (
32  A new target strategy in the development of bacterial vaccines, the induction of antibodies to micro
33 trophic bacteria as promising candidates for bacterial vaccine therapy and outline a platform for exp
34 ended application as an endpoint measure for bacterial vaccine trials.
35 sistance marker-free DNA vaccines as well as bacterial vaccine vectors devoid of engineered antibioti
36                                         Most bacterial vaccines work for a subset of bacterial strain